- Second Circuit Agrees that Copay Assistance Programs May Violate the Anti-Kickback Statute August 5, 2022
- ACI’s Paragraph IV Disputes Master Symposium – September 21-22, 2022 (Chicago) August 5, 2022
- ACI’s FDA Boot Camp – September 14-15, 2022 (Virtual) August 5, 2022
- Teva Gets Knocked Down, But It Gets Up Again—and Petitions SCOTUS August 4, 2022
- It’s My Party and I’ll Cry if I Want to: A Bittersweet Happy 30th Birthday to LDTs August 3, 2022
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
USDA/APHIS Announces Public Meeting on its Proposed Rule on Genetically Engineered Organisms
April 13, 2009By Ricardo Carvajal –
The USDA Animal and Plant Health Inspection Service (“APHIS”) will hold a public meeting on April 29 and 30 to foster discussion of certain issues that were raised during the comment period for its proposed rule on Importation, Interstate Movement, and Release into the Environment of Certain Genetically Engineered Organisms. The agency has also reopened and extended the comment period for the proposed rule until June 29. Discussion during the public meeting will focus on:
(1) Scope of the regulation and which [Genetically Engineered (“GE”)] organisms should be regulated;
(2) Incorporation into APHIS regulations of the Plant Protection Act’s noxious weed authority;
(3) Elimination of notification procedure and revision of the permit procedure;
(4) Environmental release permit categories and regulation of GE crops that produce pharmaceutical and industrial compounds.
As we noted in a prior posting, APHIS hosted a scoping session on March 13 to ferret out additional significant issues that might merit discussion at the public meeting. No word yet on which additional issues, if any, APHIS considers worthy of inclusion in the agenda for the public meeting.
Search FDA Law Blog
Subscribe
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- The Best
Lawyers in America
US News & World Report - Ranked in Chambers USA 2018
- Second Circuit Agrees that Copay Assistance Programs May Violate the Anti-Kickback Statute August 5, 2022
- ACI’s Paragraph IV Disputes Master Symposium – September 21-22, 2022 (Chicago) August 5, 2022
- ACI’s FDA Boot Camp – September 14-15, 2022 (Virtual) August 5, 2022
- Teva Gets Knocked Down, But It Gets Up Again—and Petitions SCOTUS August 4, 2022
- It’s My Party and I’ll Cry if I Want to: A Bittersweet Happy 30th Birthday to LDTs August 3, 2022
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized